Quick Answer
Aspire Biopharma Holdings, Inc. reported R&D Expense of $923.9 thousand for fiscal year 2025.
Aspire Biopharma Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $923.9K | +540.0% |
| 2024 | $144.4K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $207.9K | +2870.0% | -41.1% |
| June 30, 2025 | $352.9K | +3260.8% | +34.1% |
| March 31, 2025 | $263.1K | +2405.6% | +3658.5% |
| September 30, 2024 | $7.0K | — | -33.3% |
| June 30, 2024 | $10.5K | — | +0.0% |
| March 31, 2024 | $10.5K | — | — |
- Aspire Biopharma Holdings, Inc. showed an increase of +540.0% in R&D Expense compared to the prior fiscal year.
- Over the 2024–2025 period, Aspire Biopharma Holdings, Inc.’s r&d expense has grown by 540.0% (from $144.4 thousand to $923.9 thousand).
- The most recent figure is from Aspire Biopharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: